Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Clinical Trial Comparing Gemcitabine and Vandetanib Therapy With Gemcitabine Alone in Pancreatic Carcinoma (ViP)

The recruitment status of this study is unknown because the information has not been verified recently.
Verified May 2012 by University of Liverpool.
Recruitment status was  Recruiting
Sponsor:
Collaborator:
AstraZeneca
Information provided by (Responsible Party):
Dr Gary MIddleton, University of Liverpool
ClinicalTrials.gov Identifier:
NCT01601808
First received: February 22, 2012
Last updated: May 16, 2012
Last verified: May 2012

February 22, 2012
May 16, 2012
October 2011
October 2012   (final data collection date for primary outcome measure)
Overall survival [ Time Frame: Analysis will be carried out when all patients have a minimum of 1-year follow-up after randomisation ] [ Designated as safety issue: No ]
To assess whether survival times for patients receiving gemcitabine plus vandetanib are longer than for those patients receiving gemcitabine alone as first line treatment for advanced pancreatic cancer
Same as current
Complete list of historical versions of study NCT01601808 on ClinicalTrials.gov Archive Site
  • Progression-free survival time [ Time Frame: Analysis will be carried out when all patients have a minimum of 1-year follow-up after randomisation ] [ Designated as safety issue: No ]
  • Objective response rate [ Time Frame: Analysis will be carried out when all patients have a minimum of 1-year follow-up after randomisation ] [ Designated as safety issue: No ]
  • Disease control rate [ Time Frame: Analysis will be carried out when all patients have a minimum of 1-year follow-up after randomisation ] [ Designated as safety issue: No ]
  • Number and types of adverse events [ Time Frame: Analysis will be carried out when all patients have a minimum of 1-year follow-up after randomisation ] [ Designated as safety issue: Yes ]
  • Patient pain assessment [ Time Frame: Analysis will be carried out when all patients have a minimum of 1-year follow-up after randomisation ] [ Designated as safety issue: No ]
Same as current
Not Provided
Not Provided
 
Clinical Trial Comparing Gemcitabine and Vandetanib Therapy With Gemcitabine Alone in Pancreatic Carcinoma
A Prospective, Phase II, Double Blinded, Multicentre, Randomised Clinical Trial Comparing Combination Gemcitabine and Vandetanib Therapy With Gemcitabine Therapy Alone in Locally Advanced or Metastatic Pancreatic Carcinoma

ViP is a double blinded clinical trial which will compare gemcitabine and vandetanib chemotherapy with gemcitabine alone in patients with locally advanced or metastatic pancreatic carcinoma.

Not Provided
Interventional
Phase 2
Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Investigator)
Primary Purpose: Treatment
Pancreatic Cancer
  • Drug: Placebo
    Orally once a day, continuously throughout the study
  • Drug: Caprelsa (vandetanib)
    Orally once a daily, continuously throughout the study.
  • Placebo Comparator: Gemcitabine and Placebo
    Standard therapeutic arm. Placebo orally once a day continuously together with gemcitabine 1000mg/m2 weekly as a 30 minute infusion for 7 consecutive weeks. This will then be followed by a one week break and then gemcitabine 1000mg/m2 weekly as a 30 minute infusion for 3 weeks followed by a one week break in subsequent cycles.
    Intervention: Drug: Placebo
  • Experimental: Gemcitabine and vandetanib
    Experimental arm. Vandetanib orally once a day continuously together with gemcitabine 1000mg/m2 weekly as a 30 minute infusion for 7 consecutive weeks. This will then be followed by a one week break and then gemcitabine 1000mg/m2 weekly as a 30 minute infusion for 3 weeks followed by a one week break in subsequent cycles.
    Intervention: Drug: Caprelsa (vandetanib)
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruiting
120
October 2013
October 2012   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Age ≥ 18 years.
  • Histologically or cytologically proven pancreatic ductal adenocarcinoma or undifferentiated carcinoma of the pancreas.
  • Locally advanced or metastatic disease precluding curative surgical resection or definitive locally directed therapies such as chemo radiation. Patients who have relapsed following previously resected Pancreatic Cancer can be included.
  • Contrast enhanced computerised tomography (CT) scan of the thorax, abdomen and pelvis within 28 days prior to commencing treatment.
  • Unidimensionally measurable disease as shown by CT scan, in accordance with RECIST guidelines (version 1.1)
  • ECOG performance status 0, 1 or 2 where the investigator feels that treatment with combination chemotherapy.
  • Platelets ≥100 x 109/l; WBC ≥ 3 x 109/l; neutrophils ≥ 1.5 x 109/l at entry.
  • Documented Life expectancy > 3 months.
  • Informed written consent

Exclusion Criteria:

  • Laboratory results:

    • Serum bilirubin ≥ 1.5x the upper limit of reference range (ULRR).
    • Haemoglobin < 10G/dl
    • Creatinine clearance < 30 mL/minute (calculated by Cockcroft-Gault formula)**. Patients with a creatinine clearance of ≥30mL/minute and <50mL/minute should begin vandetanib on a reduced dose of 200mg.
    • Potassium, ≤4.0 mmol/L despite supplementation; or > 5.5 mmol/L
    • Magnesium below the normal range despite supplementation, or > 1.23 mmol/L
    • Serum calcium is > 2.9 mmol/L. In cases where serum calcium is below the normal range this can be substituted with the value for calcium adjusted for albumin, if this is below the normal range despite supplementation patients should be excluded.
    • Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) or alkaline phosphatase (ALP) >2.5 x ULRR or > 5x ULRR if judged by the investigator to be related to liver metastases.
  • Medical or psychiatric conditions compromising informed consent.
  • Intracerebral metastases or meningeal carcinomatosis.
  • Major surgery within 4 weeks or incompletely healed surgical incision before starting study therapy.
  • Evidence of severe or uncontrolled systemic disease or any concurrent condition
  • Clinically significant cardiovascular eventclassification of heart disease ≥2 within 3 months before entry; or presence of cardiac disease that, in the opinion of the Investigator, increases the risk of ventricular arrhythmia.
  • History of arrhythmia which is symptomatic or requires treatment (CTCAE grade 3) or asymptomatic sustained ventricular tachycardia. Atrial fibrillation, controlled on medication is not excluded.
  • QTc prolongation with other medications that required discontinuation of that medication.
  • Congenital long QT syndrome or 1st degree relative with unexplained sudden death under 40 years of age.
  • Presence of left bundle branch block (LBBB).
  • QTc with Bazett's correction that is un-measurable or ≥ 480 msec on screening ECG. Patients who are receiving a drug that has a risk of inducing Torsades-de-Pointes are excluded if QTc is ≥ 460 msec.
  • Any concurrent medication with a known risk of inducing Torsades-de-Pointes, that in the investigator's opinion cannot be discontinued, are allowed.
  • Concomitant medications that are potent inducers.
  • Hypertension not controlled by medical therapy.
  • Currently active diarrhoea.
  • Malabsorption syndrome.
  • Pregnancy or breast feeding.
  • Previous chemotherapy for locally advanced and metastatic disease. Adjuvant chemotherapy for resected pancreatic cancer will be permitted provided that chemotherapy was completed > 12 months previously.
  • Radiotherapy within the last 4 weeks prior to start of study treatment.
  • Concurrent malignancies or invasive cancers diagnosed within past 5 years.
  • Chemotherapy directed at tumour apart from that described in this protocol.
  • All men or women of reproductive potential, unless using at least two contraceptive precautions, one of which must be a condom.
Both
18 Years and older
No
Contact: Zaira Yunus 0151 7948935 zyunus@liv.ac.uk
United Kingdom
 
NCT01601808
2010-021951-26, 74555382
Yes
Dr Gary MIddleton, University of Liverpool
University of Liverpool
AstraZeneca
Principal Investigator: Dr Gary Middleton Royal Surrey County Hospital NHS Foundation Trust
University of Liverpool
May 2012

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP